Sensorion SA
Climate Impact & Sustainability Data (2023, 2024, 2024-01 to 2024-06)
Reporting Period: 2023
Environmental Metrics
Social Achievements
- Strengthening the Board of Directors and senior leadership: Appointed Khalil Barrage as interim Chairman of the Board, Redmile Group as a board member, Bernd Schmidt as Chief Technical Officer, and Dr. Federico Mingozzi as board member.
Climate Goals & Targets
Medium-term Goals:
- SENS-501: Enrollment of the first two cohorts of Phase 1/2 Audiogene trial completed (H1 2025)
- GJB2-GT: Clinical Trial Applications Submission (H1 2025)
Short-term Goals:
- SENS-401 in combination with cochlear implantation: Final Data readout (Q3 2024)
- SENS-401 in Cisplatin-Induced Ototoxicity: Preliminary safety and efficacy data (September 2024)
- SENS-501: Communication on first patient (H2 2024)
Environmental Challenges
- Liquidity risk due to being a clinical-stage biotech company with no marketed drugs.
- Risks related to uncertain capital resources and uncertain additional financing.
- Risks related to the clinical development of projects (delays, recruitment difficulties, regulatory hurdles).
- Risks related to the highly innovative nature of the Company's products and the early nature of their development.
- Market and competition risks.
- Risks related to the Company's commercial and strategic development (finding industrial partners).
- Risks of dependence on third parties (partners, subcontractors).
- Risks related to managing the Company's growth.
- Risks related to a restrictive and evolving regulatory framework.
- Specific risks related to preclinical studies and clinical trials.
- Risks related to patent and license portfolios.
- Product liability risks.
- Risks related to potential conflicts with potential licensees.
Mitigation Strategies
- Completed a €35 million private placement financing.
- Completed a €50.5 million reserved offering.
- Close follow-up of clinical trial sites to address recruitment challenges.
- Disciplined capital allocation approach.
- Seeking industrial collaborations and licensing agreements.
- Implementing measures to manage growth and internal resources.
- Close monitoring of regulatory developments.
- Active policy of protecting intellectual property rights.
- Maintaining adequate insurance coverage.
- Proactive risk management and mitigation strategies.
Supply Chain Management
Climate-Related Risks & Opportunities
Reporting Period: 2024
Environmental Metrics
Climate Goals & Targets
Supply Chain Management
Climate-Related Risks & Opportunities
Reporting Period: 2024-01 to 2024-06
Environmental Metrics
Social Achievements
- Strengthening the Board of Directors and the Management Team: Appointed Dr. Federico Mingozzi as board member and Laurene Danon as Chief Financial Officer.
Climate Goals & Targets
Medium-term Goals:
- GJB2-GT: Clinical Trial Applications filing in H2 2025
Short-term Goals:
- Recruitment completion of the two first cohorts of patients in SENS-501 trial expected in H1 2025.
Environmental Challenges
- Tax investigation related to the application of legislation relating to the tax on salaries for fiscal years 2020, 2021 and 2022 resulting in a tax reassessment proposal of €505k.
Mitigation Strategies
- Contested the tax reassessment and intends to continue discussion with tax authorities to limit the impact.
Supply Chain Management
Climate-Related Risks & Opportunities
Reporting Standards
Frameworks Used: IAS 34